What is Fulgent Genetics, Inc.'s earnings per share (EPS)?

Fulgent Genetics, Inc. (FLGT) reported diluted earnings per share of -$1.97 for fiscal year 2025. This represents a -39.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fulgent Genetics, Inc. (FLGT) Financials

FLGT

Trailing 12 months to June 30, 2026

Revenue $323.9M +6.8% YoY

Net Income -$84.4M -65.4% YoY

EPS (Diluted) -$2.82 -69.9% YoY

Free Cash Flow -$103.8M -73.1% YoY

Market Cap $562.7M as of Sep 12, 2026

Price / Sales 1.7x on $323.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.6x on $1.0B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FLGT SEC filings page.

Fulgent Genetics, Inc. (FLGT) reported $323.9M in revenue over the twelve months to Jun 30, 2026, up 6.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FLGT FY2025 2026-08-30

Revenue has recovered modestly, but operating costs and cash use still outrun gross-profit improvement.

Compared with FY2024, FY2025 revenue recovered while gross margin expanded to 40.6%, indicating better contribution per dollar but not enough scale to absorb overhead. Yet operating loss widened to $91.1M as SG&A and R&D reached $170.6M, so the incremental gross profit was consumed below gross profit.

Cash conversion deteriorated sharply: the FY2025 net loss of $60.5M was smaller than operating cash flow of -$101.6M, indicating working-capital or other non-cash movements amplified cash use beyond reported earnings. Free cash flow of -$124.2M also reflects $22.6M of capital expenditures, so reinvestment added to—not caused—the operating cash shortfall.

Financing pressure is not currently debt-led: FY2025 debt-to-equity was 0.1x and the current ratio was 6.5x, indicating substantial short-term asset coverage relative to near-term obligations. Still, equity declined from $1.16B in FY2021 to $1.11B in FY2025, showing that continuing losses have begun eroding the capital cushion despite minimal debt.

Financial Health Signals

Financial Health Score 44/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Fulgent Genetics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Fulgent Genetics, Inc. has an operating margin of -28.2%, meaning the company loses $28 on every $100 of revenue. This results in a profitability score of 8/100. This is down from -26.1% the prior year.

Growth

Fulgent Genetics, Inc.'s revenue grew 13.8% year-over-year to $322.7M, a solid pace of expansion. This earns a growth score of 53/100.

Leverage

Fulgent Genetics, Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 6.48, Fulgent Genetics, Inc. holds $6.48 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.

Cash Flow

Fulgent Genetics, Inc.'s operations used $101.6M of cash, and capex of $22.6M added to the outflow, for a free cash flow shortfall of $124.2M. This results in a cash flow score of 8/100.

Returns

Fulgent Genetics, Inc. posts a -5.4% return on equity (ROE), meaning it loses $5 for every $100 of shareholders' equity. This results in a returns score of 16/100. This is down from -3.8% the prior year.

Altman Z-Score Safe

4.25

Fulgent Genetics, Inc. scores 4.25, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($562.7M) relative to total liabilities ($106.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Fulgent Genetics, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Fulgent Genetics, Inc. reported a net loss of $60.5M while operations used $101.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Fulgent Genetics, Inc. reported an operating loss of $91.1M against $75K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$85.4M

YoY+4.4%

QoQ+20.0%

5Y CAGR-11.1%

10Y CAGR+35.9%

Fulgent Genetics, Inc. generated $85.4M in revenue in Q2 2026. This represents an increase of 4.4% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.

EBITDA

-$28.4M

YoY-106.6%

QoQ+0.8%

Fulgent Genetics, Inc.'s EBITDA was -$28.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 106.6% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Net Income

-$29.5M

YoY-55.8%

QoQ-18.9%

Fulgent Genetics, Inc. reported -$29.5M in net income in Q2 2026. This represents a decrease of 55.8% from the same quarter a year earlier. Against the prior quarter it is down 18.9%.

EPS (Diluted)

-$1.05

YoY-69.4%

QoQ-31.3%

Fulgent Genetics, Inc. earned -$1.05 per diluted share (EPS) in Q2 2026. This represents a decrease of 69.4% from the same quarter a year earlier. Against the prior quarter it is down 31.3%.

Cash & Balance Sheet

Free Cash Flow

-$27.6M

YoY+25.4%

QoQ-1557.3%

Fulgent Genetics, Inc. recorded an outflow of $27.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 25.4% from the same quarter a year earlier. Against the prior quarter it is down 1557.3%.

Cash & Debt

$26.3M

YoY-70.1%

QoQ+12.4%

5Y CAGR-23.5%

Fulgent Genetics, Inc. held $26.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

28M

YoY-10.1%

QoQ-3.1%

5Y CAGR-1.4%

Fulgent Genetics, Inc. had 28M shares outstanding in Q2 2026. This represents a decrease of 10.1% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

30.1%

YoY-12.0pp

QoQ-0.1pp

5Y change-46.6pp

10Y change-34.4pp

Fulgent Genetics, Inc.'s gross margin was 30.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 12.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Operating Margin

-42.3%

YoY-18.1pp

QoQ+6.4pp

5Y change-106.6pp

10Y change-66.7pp

Fulgent Genetics, Inc.'s operating margin was -42.3% in Q2 2026, reflecting core business profitability. This is down 18.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.4 percentage points.

Net Margin

-34.6%

YoY-11.4pp

QoQ+0.3pp

5Y change-86.5pp

Fulgent Genetics, Inc.'s net profit margin was -34.6% in Q2 2026, showing the share of revenue converted to profit. This is down 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.

Return on Equity

-2.9%

YoY-1.2pp

QoQ-0.6pp

5Y change-11.7pp

Fulgent Genetics, Inc.'s ROE was -2.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.

Capital Allocation

R&D Spending

$14.6M

YoY+8.0%

QoQ+2.7%

5Y CAGR+22.3%

10Y CAGR+36.3%

Fulgent Genetics, Inc. invested $14.6M in research and development in Q2 2026. This represents an increase of 8.0% from the same quarter a year earlier. Against the prior quarter it is up 2.7%.

Share Buybacks

$23.8M

YoY+979.6%

QoQ-40.6%

Fulgent Genetics, Inc. spent $23.8M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 979.6% from the same quarter a year earlier. Against the prior quarter it is down 40.6%.

Capital Expenditures

$3.9M

YoY-43.5%

QoQ-25.8%

5Y CAGR+5.6%

10Y CAGR+25.9%

Fulgent Genetics, Inc. invested $3.9M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 43.5% from the same quarter a year earlier. Against the prior quarter it is down 25.8%.

FLGT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FLGT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$323.9M	$322.7M+13.8%	$283.5M-2.0%	$289.2M-53.3%	$619.0M-37.6%	$992.6M+135.4%	$421.7M+1196.5%	$32.5M+52.3%	$21.4M+14.0%	$18.7M+2.5%	$18.3M+90.9%	$9.6M+649.3%	$1.3M
Cost of Revenue	$208.7M	$191.8M+8.8%	$176.3M-4.6%	$184.8M-26.7%	$252.1M+17.0%	$215.5M+140.0%	$89.8M	$0	$0-100.0%	$8.6M+27.2%	$6.7M+32.6%	$5.1M+441.6%	$936K
Gross Profit	$115.3M	$130.9M+22.1%	$107.2M+2.6%	$104.5M-71.5%	$366.9M-52.8%	$777.1M+134.1%	$331.9M+1701.8%	$18.4M+72.9%	$10.7M+4.7%	$10.2M-11.9%	$11.6M+156.4%	$4.5M+1217.8%	$342K
R&D Expenses	$56.8M	$53.9M+10.4%	$48.8M+17.8%	$41.4M+43.3%	$28.9M+19.4%	$24.2M+109.1%	$11.6M+77.1%	$6.5M+18.1%	$5.5M+31.0%	$4.2M+18.7%	$3.6M-19.7%	$4.4M+750.5%	$521K
SG&A Expenses	$119.9M	$116.7M+32.4%	$88.1M-1.0%	$89.0M-19.9%	$111.1M+118.9%	$50.7M+233.4%	$15.2M+137.2%	$6.4M+15.8%	$5.5M+5.8%	$5.2M+13.5%	$4.6M+90.6%	$2.4M+951.3%	$230K
Operating Income	-$122.3M	-$91.1M-23.2%	-$73.9M+62.2%	-$195.5M-209.5%	$178.5M-73.6%	$676.0M+133.0%	$290.2M+67893.9%	-$428K+91.6%	-$5.1M-45.6%	-$3.5M-479.3%	$918K+118.3%	-$5.0M-406.3%	-$990K
EBITDA	N/A	-$67.0M-36.7%	-$49.0M+71.1%	-$169.4M-180.2%	$211.2M-69.3%	$687.0M+134.4%	$293.1M+17358.0%	$1.7M+157.8%	-$2.9M-65.7%	-$1.8M-184.0%	$2.1M+147.1%	-$4.4M-458.8%	-$794K
Interest Expense	$120K	$75K+144.1%	-$170K-134.8%	$488K+41.0%	$346K+195.7%	$117K+485.0%	$20K	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$7.0M	-$8.4M-3.2%	-$8.1M-805.0%	$1.2M-97.3%	$42.1M-75.9%	$174.8M+141.0%	$72.5M+168579.1%	$43K+19.4%	$36K+103.5%	-$1.0M-210.3%	$920K	$0	$0
Net Income	-$84.4M	-$60.5M-41.7%	-$42.7M+74.6%	-$167.8M-217.0%	$143.4M-71.7%	$507.4M+136.7%	$214.3M+52243.6%	-$411K+92.7%	-$5.6M-123.4%	-$2.5M+53.1%	-$5.3M+35.7%	-$8.3M-94.1%	-$4.3M
EPS (Basic)	N/A	-$1.97-39.7%	-$1.41+75.0%	-$5.63-218.3%	$4.76-72.4%	$17.25+82.7%	$9.44+47300.0%	-$0.02+93.5%	-$0.31-121.4%	-$0.14	N/A	N/A	N/A
EPS (Diluted)	-$2.82	-$1.97-39.7%	-$1.41+75.0%	-$5.63-221.6%	$4.63-71.7%	$16.38+83.8%	$8.91+44650.0%	-$0.02+93.5%	-$0.31-121.4%	-$0.14	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	31M+1.8%	30M+1.5%	30M-3.8%	31M0.0%	31M+28.8%	24M+28.6%	19M+4.1%	18M+1.3%	18M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$85.4M+4.4%	$71.1M-3.2%	$83.3M+9.3%	$84.1M+17.2%	$81.8M+15.2%	$73.5M+13.9%	$76.2M+8.1%	$71.7M-15.3%
Cost of Revenue	$59.7M+26.1%	$49.6M+10.0%	$50.8M+14.4%	$48.6M+8.0%	$47.4M+6.4%	$45.1M+6.5%	$44.4M-2.0%	$45.0M+0.3%
Gross Profit	$25.7M-25.4%	$21.5M-24.2%	$32.6M+2.3%	$35.5M+32.7%	$34.4M+30.0%	$28.3M+28.2%	$31.8M+26.2%	$26.8M-32.8%
R&D Expenses	$14.6M+8.0%	$14.2M+14.4%	$14.2M+17.0%	$13.9M+17.6%	$13.5M0.0%	$12.4M+8.4%	$12.1M+1.3%	$11.8M+17.7%
SG&A Expenses	$27.2M+3.0%	$27.7M+9.5%	$41.6M+71.1%	$23.3M+11.4%	$26.4M+23.8%	$25.3M+17.7%	$24.3M-23.2%	$20.9M+19.7%
Operating Income	-$36.1M-83.0%	-$34.6M-74.9%	-$36.2M-124.6%	-$15.3M+10.1%	-$19.7M-4.3%	-$19.8M+9.2%	-$16.1M+89.3%	-$17.1M-8080.8%
EBITDA	-$28.4M-106.6%	-$28.6M-106.3%	-$30.0M-201.9%	-$9.3M+16.3%	-$13.7M-7.7%	-$13.9M+8.3%	-$9.9M+93.1%	-$11.2M-268.2%
Interest Expense	$59K+247.1%	$17K+21.4%	$16K-60.0%	$28K+100.0%	$17K-32.0%	$14K+105.6%	$40K-73.7%	$14K
Income Tax	$29K+101.3%	-$704K-500.0%	-$5.6M-204.5%	-$683K+82.2%	-$2.3M-6.5%	$176K+153.8%	-$1.8M+83.0%	-$3.8M-118.9%
Net Income	-$29.5M-55.8%	-$24.8M-115.3%	-$23.4M-297.7%	-$6.6M+54.9%	-$19.0M-117.6%	-$11.5M+14.4%	-$5.9M+95.4%	-$14.6M-11.8%
EPS (Basic)	-$1.05-69.4%	-$0.80-116.2%	-$0.76-300.0%	-$0.21+56.3%	-$0.62-113.8%	-$0.37+17.8%	-$0.19+95.6%	-$0.48-9.1%
EPS (Diluted)	-$1.05-69.4%	-$0.80-116.2%	-$0.76-300.0%	-$0.21+56.3%	-$0.62-113.8%	-$0.37+17.8%	-$0.19+95.6%	-$0.48-9.1%
Diluted Shares (Avg)	28M-8.3%	31M+0.2%	N/A	31M+1.1%	31M+1.5%	31M+3.6%	N/A	30M+1.3%

FLGT Balance Sheet

FLGT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$1.2B-0.5%	$1.2B-1.2%	$1.2B-10.9%	$1.4B+8.4%	$1.3B+82.6%	$700.5M+689.2%	$88.8M+64.7%	$53.9M-5.7%	$57.2M-1.5%	$58.0M+895.2%	$5.8M	N/A
Current Assets	$550.5M+55.7%	$353.6M-30.4%	$507.8M-19.1%	$627.9M+2.6%	$612.0M+16.9%	$523.6M+1312.2%	$37.1M-6.2%	$39.5M+20.1%	$32.9M+26.0%	$26.1M+792.1%	$2.9M	N/A
Cash & Equivalents	$50.2M-9.0%	$55.1M-43.4%	$97.5M+22.6%	$79.5M-51.8%	$164.9M+88.6%	$87.4M+630.7%	$12.0M+77.6%	$6.7M+3.8%	$6.5M-17.8%	$7.9M+1514.9%	$489K	N/A
Short-Term Investments	$285.9M+40.9%	$203.0M	$0	$0	$0-100.0%	$211.9M+1199.9%	$16.3M-32.9%	$24.3M+21.5%	$20.0M+54.1%	$13.0M	$0	N/A
Accounts Receivable	$84.8M+22.8%	$69.0M+35.0%	$51.1M-3.1%	$52.7M-62.0%	$138.9M-24.4%	$183.9M+2704.8%	$6.6M+10.2%	$5.9M+48.5%	$4.0M-8.2%	$4.4M+106.0%	$2.1M	N/A
Long-Term Investments	$369.3M-35.3%	$570.4M+34.7%	$423.6M+29.7%	$326.6M-32.7%	$485.0M+266.1%	$132.5M+215.9%	$41.9M+556.9%	$6.4M-57.1%	$14.9M-41.9%	$25.6M	$0	N/A
Goodwill	$25.1M+13.7%	$22.1M0.0%	$22.1M-84.6%	$143.0M+181.0%	$50.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$106.8M+17.6%	$90.8M-11.0%	$102.0M-12.2%	$116.2M+3.0%	$112.8M-13.9%	$131.1M+2092.2%	$6.0M+117.3%	$2.8M-8.4%	$3.0M-15.6%	$3.6M+419.1%	$686K	N/A
Current Liabilities	$85.0M+16.6%	$72.9M-0.2%	$73.0M-17.1%	$88.1M-16.3%	$105.3M-19.1%	$130.1M+3394.9%	$3.7M+36.0%	$2.7M-8.7%	$3.0M-9.5%	$3.3M+383.4%	$686K	N/A
Non-Current Liabilities	$21.8M+22.0%	$17.9M-38.3%	$29.0M+3.4%	$28.1M+272.8%	$7.5M+685.2%	$959K-57.5%	$2.3M+16014.3%	$14K+133.3%	$6K-97.6%	$245K	$0	N/A
Total Equity	$1.1B-1.9%	$1.1B-0.3%	$1.1B-10.3%	$1.3B+9.3%	$1.2B+103.5%	$569.4M+587.9%	$82.8M+61.8%	$51.2M-5.6%	$54.2M-0.6%	$54.5M+958.7%	$5.1M+205.6%	$1.7M
Retained Earnings	$530.0M-10.2%	$590.5M-6.7%	$633.2M-21.0%	$801.0M+21.8%	$657.6M+335.8%	$150.9M+337.9%	-$63.4M-0.7%	-$63.0M-9.3%	-$57.7M-4.6%	-$55.2M-3.8%	-$53.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.1B-9.2%	$1.2B-4.1%	$1.2B-0.5%	$1.2B-1.6%	$1.2B-2.6%	$1.2B-2.0%	$1.2B-1.2%	$1.2B-9.2%
Current Assets	$454.8M+6.1%	$479.0M+14.9%	$550.5M+55.7%	$507.4M+55.4%	$428.7M+7.4%	$416.8M+7.8%	$353.6M-30.4%	$326.5M-40.6%
Cash & Equivalents	$26.3M-70.1%	$23.4M-65.2%	$50.2M-9.0%	$117.6M+102.7%	$87.9M+35.0%	$67.3M+23.1%	$55.1M-43.4%	$58.0M-31.0%
Short-Term Investments	$230.7M	$252.9M	$285.9M+40.9%	$0	$0	$0	$203.0M	$0
Inventory	$793K	$770K	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$64.9M-15.9%	$69.3M-3.1%	$84.8M+22.8%	$71.2M+24.2%	$77.2M+36.4%	$71.5M+37.3%	$69.0M+35.0%	$57.3M+16.3%
Long-Term Investments	$294.3M-39.3%	$328.3M-33.6%	$369.3M-35.3%	$411.8M-31.6%	$484.5M-7.9%	$494.1M-8.6%	$570.4M+34.7%	$602.2M+57.0%
Goodwill	$53.9M+144.2%	$53.7M+143.6%	$25.1M+13.7%	$25.1M+13.7%	$22.1M0.0%	$22.1M0.0%	$22.1M0.0%	$22.1M-84.5%
Total Liabilities	$93.2M+5.7%	$112.2M+35.2%	$106.8M+17.6%	$93.8M-5.1%	$88.2M-14.7%	$83.0M-19.6%	$90.8M-11.0%	$98.9M+2.4%
Current Liabilities	$71.8M+0.6%	$90.1M+36.7%	$85.0M+16.6%	$72.4M-2.1%	$71.3M-5.8%	$65.9M-13.2%	$72.9M-0.2%	$74.0M+20.5%
Non-Current Liabilities	$21.5M+27.4%	$22.1M+29.4%	$21.8M+22.0%	$21.4M-14.1%	$16.9M-39.0%	$17.1M-37.5%	$17.9M-38.3%	$24.9M-29.2%
Total Equity	$1.0B-10.3%	$1.0B-6.9%	$1.1B-1.9%	$1.1B-1.1%	$1.1B-1.4%	$1.1B-0.2%	$1.1B-0.3%	$1.1B-9.6%
Retained Earnings	$475.6M-15.1%	$505.1M-12.7%	$530.0M-10.2%	$553.4M-7.2%	$560.0M-8.4%	$578.9M-6.6%	$590.5M-6.7%	$596.4M-21.7%

Not reported in any period shown, so not listed: Long-Term Debt.

FLGT Cash Flow Statement

FLGT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$83.7M	-$101.6M-582.6%	$21.1M-22.0%	$27.0M-89.3%	$253.5M-52.9%	$538.6M+283.0%	$140.6M+2449.0%	$5.5M+917.3%	-$675K-150.7%	$1.3M-69.8%	$4.4M+554.6%	-$969K+78.0%	-$4.4M
Depreciation & Amortization	N/A	$24.1M-3.2%	$24.9M-4.6%	$26.1M-20.0%	$32.7M+196.8%	$11.0M+271.5%	$3.0M+40.6%	$2.1M-2.6%	$2.2M+25.2%	$1.7M+47.7%	$1.2M+103.5%	$575K+193.4%	$196K
Stock-Based Compensation	N/A	$39.6M-11.0%	$44.5M+3.6%	$42.9M+31.5%	$32.6M+105.5%	$15.9M+94.7%	$8.2M+154.2%	$3.2M+39.3%	$2.3M+8.7%	$2.1M-54.5%	$4.7M-42.9%	$8.2M	N/A
Capital Expenditures	$20.1M	$22.6M-44.0%	$40.3M+81.5%	$22.2M+18.3%	$18.8M-21.2%	$23.8M-32.2%	$35.1M+2872.1%	$1.2M-49.1%	$2.3M-19.8%	$2.9M-23.6%	$3.8M+80.4%	$2.1M+187.3%	$731K
Free Cash Flow	-$103.8M	-$124.2M-545.1%	-$19.3M-501.5%	$4.8M-98.0%	$234.7M-54.4%	$514.8M+387.9%	$105.5M+2333.6%	$4.3M+244.6%	-$3.0M-91.6%	-$1.6M-353.5%	$617K+120.1%	-$3.1M+40.2%	-$5.1M
Investing Cash Flow	$92.0M	$111.4M+290.9%	-$58.4M-250.0%	$38.9M+114.9%	-$261.3M+52.2%	-$546.5M-67.4%	-$326.4M-1023.9%	-$29.0M-3157.5%	$950K+146.4%	-$2.0M+95.2%	-$42.8M-1840.8%	-$2.2M-182.7%	-$780K
Financing Cash Flow	-$70.0M	-$14.8M-205.1%	-$4.8M+89.9%	-$47.8M+38.1%	-$77.1M-190.3%	$85.4M-67.3%	$261.3M+807.9%	$28.8M+191733.3%	$15K+101.9%	-$770K-101.7%	$45.8M+1208.3%	$3.5M-12.5%	$4.0M
Share Buybacks	$63.9M	$10.9M+4737.3%	$225K-99.1%	$25.1M-66.3%	$74.3M	N/A	$62K+195.2%	$21K	N/A	N/A	$12.0M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$23.8M+21.3%	$7.1M+260.2%	-$78.1M-412.3%	$11.1M+171.6%	-$30.2M-804.1%	-$4.4M-161.0%	$25.0M+67.5%	-$15.5M-251.5%
Depreciation & Amortization	$7.7M+28.7%	$6.0M+1.4%	$6.1M-1.3%	$6.0M+1.5%	$6.0M-2.9%	$5.9M-11.2%	$6.2M-5.2%	$5.9M-7.8%
Stock-Based Compensation	$8.6M-14.1%	$9.9M-6.3%	N/A	$9.7M-11.0%	$10.0M-13.7%	$10.6M-8.4%	N/A	$10.9M+0.2%
Capital Expenditures	$3.9M-43.5%	$5.2M+10.3%	$5.0M+31.8%	$6.0M-69.0%	$6.8M-47.3%	$4.7M+16.3%	$3.8M+21.6%	$19.5M+296.9%
Free Cash Flow	-$27.6M+25.4%	$1.9M+120.7%	-$83.1M-491.4%	$5.1M+114.4%	-$37.0M-327.3%	-$9.1M-385.0%	$21.2M+79.6%	-$35.0M-759.1%
Investing Cash Flow	$50.8M-4.9%	$10.9M-60.6%	$11.2M+140.6%	$19.1M+112.4%	$53.4M+631.2%	$27.7M+158.8%	-$27.5M-213.1%	$9.0M-55.2%
Financing Cash Flow	-$24.2M-818.3%	-$44.8M-301.3%	-$534K-63.3%	-$445K+21.5%	-$2.6M-130.2%	-$11.2M-298.0%	-$327K+98.7%	-$567K+87.3%
Share Buybacks	$23.8M+979.6%	$40.1M+361.8%	$0	$0	$2.2M	$8.7M+3757.3%	$0-100.0%	$0

Not reported in any period shown, so not listed: Dividends Paid.

FLGT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FLGT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	40.6%+2.7pp	37.8%+1.7pp	36.1%-23.2pp	59.3%-19.0pp	78.3%-0.4pp	78.7%+22.1pp	56.6%+6.7pp	49.9%-4.4pp	54.4%-8.9pp	63.2%+16.1pp	47.1%+20.3pp	26.8%
Operating Margin	-28.2%-2.2pp	-26.1%+41.5pp	-67.6%-96.5pp	28.8%-39.3pp	68.1%-0.7pp	68.8%+70.1pp	-1.3%+22.4pp	-23.8%-5.2pp	-18.6%-23.6pp	5.0%+57.4pp	-52.3%+25.1pp	-77.5%
Net Margin	-18.8%-3.7pp	-15.1%+43.0pp	-58.0%-81.2pp	23.2%-27.9pp	51.1%+0.3pp	50.8%+52.1pp	-1.3%+25.0pp	-26.3%-12.9pp	-13.4%+15.9pp	-29.3%+57.6pp	-86.8%	-335.1%
Return on Equity	-5.4%-1.7pp	-3.8%+11.0pp	-14.8%-26.1pp	11.3%-32.5pp	43.8%+6.2pp	37.6%+38.1pp	-0.5%+10.5pp	-11.0%-6.3pp	-4.6%+5.2pp	-9.8%+151.7pp	-161.6%+92.8pp	-254.3%
Return on Assets	-5.0%-1.5pp	-3.5%+10.1pp	-13.6%-23.9pp	10.3%-29.3pp	39.7%+9.1pp	30.6%+31.1pp	-0.5%+9.9pp	-10.4%-6.0pp	-4.4%+4.8pp	-9.2%+133.3pp	-142.6%	N/A
Current Ratio	6.48+1.6x	4.85-2.1x	6.96-0.2x	7.13+1.3x	5.81+1.8x	4.02-5.9x	9.96-4.5x	14.44+3.5x	10.98+3.1x	7.88+3.6x	4.27	N/A
Debt-to-Equity	0.100.0x	0.080.0x	0.090.0x	0.090.0x	0.10-0.1x	0.23+0.2x	0.070.0x	0.050.0x	0.060.0x	0.07-0.1x	0.13	N/A
Asset Turnover	0.270.0x	0.230.0x	0.23-0.2x	0.45-0.3x	0.78+0.2x	0.60+0.2x	0.370.0x	0.40+0.1x	0.330.0x	0.31-1.3x	1.64	N/A
FCF Margin	-38.5%-31.7pp	-6.8%-8.5pp	1.7%-36.3pp	37.9%-13.9pp	51.9%+26.8pp	25.0%+11.7pp	13.3%+27.4pp	-14.0%-5.7pp	-8.3%-11.7pp	3.4%+35.4pp	-32.0%	-401.3%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	30.1%-12.0pp	30.2%-8.4pp	39.1%-2.7pp	42.2%+4.9pp	42.1%+4.8pp	38.6%+4.3pp	41.8%+6.0pp	37.3%-9.7pp
Operating Margin	-42.3%-18.1pp	-48.7%-21.7pp	-43.5%-22.3pp	-18.3%+5.5pp	-24.1%+2.5pp	-27.0%+6.9pp	-21.2%	-23.8%-24.1pp
Net Margin	-34.6%-11.4pp	-34.9%-19.2pp	-28.1%-20.4pp	-7.9%+12.6pp	-23.2%-10.9pp	-15.7%+5.2pp	-7.7%	-20.4%-4.9pp
Return on Equity	-2.9%-1.2pp	-2.4%-1.3pp	-2.1%-1.6pp	-0.6%+0.7pp	-1.7%-0.9pp	-1.0%+0.2pp	-0.5%+10.8pp	-1.3%-0.3pp
Return on Assets	-2.7%-1.1pp	-2.1%-1.2pp	-1.9%-1.5pp	-0.5%+0.7pp	-1.6%-0.9pp	-1.0%+0.1pp	-0.5%+9.9pp	-1.2%-0.2pp
Current Ratio	6.34+0.3x	5.31-1.0x	6.48+1.6x	7.01+2.6x	6.01+0.7x	6.32+1.2x	4.85-2.1x	4.41-4.5x
Debt-to-Equity	0.090.0x	0.110.0x	0.100.0x	0.080.0x	0.080.0x	0.070.0x	0.080.0x	0.090.0x
Asset Turnover	0.080.0x	0.060.0x	0.070.0x	0.070.0x	0.070.0x	0.060.0x	0.060.0x	0.060.0x
FCF Margin	-32.3%+12.9pp	2.7%+15.1pp	-99.7%-127.6pp	6.0%+54.9pp	-45.2%-33.0pp	-12.4%-17.4pp	27.9%+11.1pp	-48.9%-55.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Fulgent Genetics, Inc. FLGT	FY2025	$322.7M	-$60.5M	-18.8%	$562.7M	44/100
Castle Biosciences, Inc. CSTL	FY2025	$344.2M	-$24.2M	-7.0%	$987.4M	61/100
Myriad Genetics Inc MYGN	FY2025	$824.5M	-$366.0M	-44.4%	$321.4M	38/100
CareDx, Inc. CDNA	FY2025	$379.8M	-$21.4M	-5.6%	$2.6B	43/100
Personalis, Inc. PSNL	FY2025	$69.6M	-$81.3M	N/A	$1.7B	51/100
NeoGenomics, Inc. NEO	FY2025	$727.3M	-$108.0M	-14.8%	$2.3B	51/100

Where Fulgent Genetics, Inc. Ranks

Frequently Asked Questions

What is Fulgent Genetics, Inc.'s annual revenue?

Fulgent Genetics, Inc. (FLGT) reported $322.7M in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fulgent Genetics, Inc.'s revenue growing?

Fulgent Genetics, Inc. (FLGT) revenue grew by 13.8% year-over-year, from $283.5M to $322.7M in fiscal year 2025.

Is Fulgent Genetics, Inc. profitable?

No, Fulgent Genetics, Inc. (FLGT) reported a net income of -$60.5M in fiscal year 2025, with a net profit margin of -18.8%.

What is Fulgent Genetics, Inc.'s EBITDA?

Fulgent Genetics, Inc. (FLGT) had EBITDA of -$67.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Fulgent Genetics, Inc.'s gross margin?

Fulgent Genetics, Inc. (FLGT) had a gross margin of 40.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fulgent Genetics, Inc.'s operating margin?

Fulgent Genetics, Inc. (FLGT) had an operating margin of -28.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Fulgent Genetics, Inc.'s net profit margin?

Fulgent Genetics, Inc. (FLGT) had a net profit margin of -18.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Fulgent Genetics, Inc.'s return on equity (ROE)?

Fulgent Genetics, Inc. (FLGT) has a return on equity of -5.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Fulgent Genetics, Inc.'s free cash flow?

Fulgent Genetics, Inc. (FLGT) recorded an outflow of $124.2M in free cash flow during fiscal year 2025. This represents a -545.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Fulgent Genetics, Inc.'s operating cash flow?

Fulgent Genetics, Inc. (FLGT) recorded an outflow of $101.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Fulgent Genetics, Inc.'s total assets?

Fulgent Genetics, Inc. (FLGT) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Fulgent Genetics, Inc.'s capital expenditures?

Fulgent Genetics, Inc. (FLGT) invested $22.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Fulgent Genetics, Inc. spend on research and development?

Fulgent Genetics, Inc. (FLGT) invested $53.9M in research and development during fiscal year 2025.

Does Fulgent Genetics, Inc. buy back shares?

Yes, Fulgent Genetics, Inc. (FLGT) spent $10.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Fulgent Genetics, Inc. have outstanding?

Fulgent Genetics, Inc. (FLGT) had 31M shares outstanding as of fiscal year 2025.

What is Fulgent Genetics, Inc.'s current ratio?

Fulgent Genetics, Inc. (FLGT) had a current ratio of 6.48 as of fiscal year 2025, which is generally considered healthy.

What is Fulgent Genetics, Inc.'s debt-to-equity ratio?

Fulgent Genetics, Inc. (FLGT) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fulgent Genetics, Inc.'s return on assets (ROA)?

Fulgent Genetics, Inc. (FLGT) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Fulgent Genetics, Inc.'s P/E ratio?

Fulgent Genetics, Inc. (FLGT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $562.7M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Fulgent Genetics, Inc.'s price-to-sales ratio?

Fulgent Genetics, Inc. (FLGT) trades at 1.7x sales, its market capitalization divided by revenue of $323.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $562.7M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Fulgent Genetics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Fulgent Genetics, Inc. (FLGT) held $705.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $101.6M over that year. Dividing the one by the other, the reported balance equals about 83 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Fulgent Genetics, Inc.'s Altman Z-Score?

Fulgent Genetics, Inc. (FLGT) has an Altman Z-Score of 4.25, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Fulgent Genetics, Inc.'s Piotroski F-Score?

Fulgent Genetics, Inc. (FLGT) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fulgent Genetics, Inc.'s earnings high quality?

Fulgent Genetics, Inc. (FLGT) reported a net loss of $60.5M while operations used $101.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fulgent Genetics, Inc. cover its interest payments?

Fulgent Genetics, Inc. (FLGT) reported an operating loss of $91.1M against $75K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Fulgent Genetics, Inc.?

Fulgent Genetics, Inc. (FLGT) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.